Zasocitinib demonstrated high rates of psoriasis clearance for hard-to-treat areas and high-impact sites, Takeda announced in a press release.Approximately 75% of participants with scalp psoriasis and 70% of those with palmoplantar psoriasis who received zasocitinib — a selective oral tyrosine kinase 2 (TYK2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis — achieved clear or almost clear skin within…
Source: Healio News
